Therapeutic Asset Ratings

223 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Cetuximab Lung Cancer	Merck Sharp & Dohme LLC	P3	B (62)
Crizotinib Lung Cancer	Sun Yat-sen University	P3	B (62)
FILGRASTIM Lung Cancer	University of Washington	P3	B (62)
Pembrolizumab Lung Cancer	City of Hope Medical Center	P3	B (62)
PANITUMUMAB Lung Cancer	Institut de Recherches Internationales Servier	P2	B (62)
ALECTINIB Lung Cancer	Joshua Palmer	P4	B (61)
TRASTUZUMAB Lung Cancer	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	P2	B (61)
Durvalumab Lung Cancer	University of Chicago	P3	B (60)
Famitinib Lung Cancer	Hansoh BioMedical R&D Company	P3	B (60)
Icotinib Lung Cancer	Fuzhou General Hospital	P3	B (60)
Lurbinectedin Lung Cancer	SystImmune Inc.	P3	B (60)
Pyrotinib Lung Cancer	Gustave Roussy, Cancer Campus, Grand Paris	P3	B (60)
Calcium folinate pentahydrate Lung Cancer	Tango Therapeutics, Inc.	P2/3	B (60)
FLUOROURACILUM Lung Cancer	Tango Therapeutics, Inc.	P2/3	B (60)
Fludarabine Lung Cancer	Pfizer	P3	B (59)
rc48-adc Lung Cancer	Gustave Roussy, Cancer Campus, Grand Paris	P3	B (59)
Avutometinib Lung Cancer	Emory University	P2	B (59)
FLUDEOXYGLUCOSE Lung Cancer	Peking University Cancer Hospital & Institute	P3	B (58)
Infliximab Lung Cancer	M.D. Anderson Cancer Center	P3	B (58)
Panobinostat Lung Cancer	National Cancer Institute (NCI)	P3	B (58)
Olaparib Lung Cancer	Sichuan University	P2	B (58)
Brigatinib Lung Cancer	Fundación GECP	P3	B (57)
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER Lung Cancer	City of Hope Medical Center	P2	B (57)
Letrozole Lung Cancer	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	P2	B (57)
TIL Lung Cancer	Essen Biotech	P2	B (57)

Showing 26 to 50 of 223 assets

PreviousPage 2 of 9Next